Context Therapeutics (STU:6K9) Stock Based Compensation: €1.37 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:6K9 Context Therapeutics Inc STU:6K9
36 GF Score
Price €0.44
! 1 Warning Sign
View Full Analysis

What is Context Therapeutics Stock Based Compensation?

Context Therapeutics STU:6K9 +6.86% 36 Stock Based Compensation is €1.37 Mil as of Jun. 2026. GuruFocus rates STU:6K9 with a GF Score™ of 36/100. The stock has 1 warning sign investors should review.

Context Therapeutics's Stock Based Compensation for the three months ended in Jun. 2026 was €0.46 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2026 was €1.37 Mil.

Context Therapeutics Stock Based Compensation Related Terms

Context Therapeutics Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Context Therapeutics's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Context Therapeutics Stock Based Compensation Chart

Context Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial 0.45 0.92 0.99 0.80 1.14

Context Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.34 0.28 0.28 0.35 0.46
STU:6K9
36GF Score
Context Therapeutics Inc STU:6K9
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Context Therapeutics Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €1.37 Mil.

What does a Stock Based Compensation of €1.37 Mil mean?
Context Therapeutics (STU:6K9) has a Stock Based Compensation of €1.37 Mil as of Jun. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Context Therapeutics and its competitors.
Is Context Therapeutics' Stock Based Compensation too high?
Context Therapeutics' current Stock Based Compensation is €1.37 Mil. Overall, Context Therapeutics has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does Context Therapeutics' Stock Based Compensation compare to INKT and XLO?
Context Therapeutics' Stock Based Compensation of €1.37 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Context Therapeutics and its competitors. Context Therapeutics's current Stock Based Compensation is €1.37 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Context Therapeutics stock overvalued right now?
Context Therapeutics (STU:6K9) has a current Stock Based Compensation of €1.37 Mil. The current Stock Based Compensation is €1.37 Mil. Context Therapeutics' overall GF Score™ is 36/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Context Therapeutics (STU:6K9), the current Stock Based Compensation is €1.37 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Context Therapeutics Business Description

Other Exchanges CNTX:USA
Address 2001 Market Street, Suite 3915, Unit No. 15, Philadelphia, PA, USA, 19103
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
36GF Score

Get the complete analysis for STU:6K9

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.44
Price